Immunitas Therapeutics
PrivateLast Round
Series B
Aug 18, 2021
Total Funding Raised
$97M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Immunitas Therapeutics is a biotechnology company that develops innovative therapeutics aimed at treating patients with complex cancers and autoimmune diseases through a single-cell genomics platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunitas Therapeutics Comparables
Compare Immunitas Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tizona Therapeutics | 81% | |
| Immune-Onc Therapeutics | 80% | |
| Coherus BioSciences Inc | 76% | |
Immunitas Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 18, 2021 | ||||
| Series A | Nov 21, 2019 |
Immunitas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B |
| 120 Capital | Series B |
| Dean Capital Investments Management | Series A |
| Mirae Asset | Series B |
| M Ventures | Series A, Series B |
| BrightEdge | Series B |
| Medical Excellence Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 93% MoM, reaching 2.3K.
- Jul 25, 2026
Monthly visitors grew 304% MoM.
Immunitas Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immunitas Therapeutics's valuation, stock price, and market status.